Nearly 30 percent of outpatient opioid prescriptions in the United
Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy
August 30, 2018 – Pfizer Inc. (NYSE: PFE) announced today
Orphazyme Announces Enrollment of First Patient in Phase III Clinical Trial of Arimoclomol for ALS
Copenhagen, August 10, 2018 – Orphazyme A/S, a biopharmaceutical company
Otonomy Initiates Phase 3 Clinical Trial of Otividex in Ménière’s Disease
SAN DIEGO, July 26, 2018 (GLOBE NEWSWIRE) — Otonomy, Inc.
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE) July 12, 2018 –Vaxart, Inc.